19.75
price up icon1.59%   0.31
pre-market  Vorhandelsmarkt:  19.84   0.09   +0.46%
loading
Schlusskurs vom Vortag:
$19.44
Offen:
$19.44
24-Stunden-Volumen:
3.23M
Relative Volume:
1.35
Marktkapitalisierung:
$14.57B
Einnahmen:
$956.00K
Nettoeinkommen (Verlust:
$-196.68M
KGV:
-82.29
EPS:
-0.24
Netto-Cashflow:
$-113.02M
1W Leistung:
-5.00%
1M Leistung:
-10.71%
6M Leistung:
-19.02%
1J Leistung:
+456.34%
1-Tages-Spanne:
Value
$19.13
$20.02
1-Wochen-Bereich:
Value
$19.13
$20.85
52-Wochen-Spanne:
Value
$2.10
$33.89

Summit Therapeutics Inc Stock (SMMT) Company Profile

Name
Firmenname
Summit Therapeutics Inc
Name
Telefon
305-203-2034
Name
Adresse
601 BRICKELL KEY DRIVE, MIAMI
Name
Mitarbeiter
159
Name
Twitter
@summitplc
Name
Nächster Verdiensttermin
2025-02-24
Name
Neueste SEC-Einreichungen
Name
SMMT's Discussions on Twitter

Vergleichen Sie SMMT mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
SMMT
Summit Therapeutics Inc
19.75 14.57B 956.00K -196.68M -113.02M -0.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
503.20 129.22B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
658.48 71.99B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
615.02 37.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
283.34 36.68B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
251.98 27.10B 3.81B -644.79M -669.77M -6.24

Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-21 Eingeleitet Cantor Fitzgerald Overweight
2025-03-12 Eingeleitet Evercore ISI Outperform
2025-02-28 Eingeleitet Goldman Buy
2025-01-08 Eingeleitet Truist Buy
2024-12-11 Eingeleitet Wells Fargo Overweight
2024-12-06 Eingeleitet Jefferies Buy
2024-11-04 Eingeleitet JMP Securities Mkt Outperform
2024-09-27 Herabstufung Citigroup Buy → Neutral
2024-08-12 Eingeleitet H.C. Wainwright Buy
2024-05-07 Eingeleitet Citigroup Buy
2024-03-26 Eingeleitet Stifel Buy
2018-06-28 Herabstufung Janney Buy → Neutral
2018-05-02 Eingeleitet Janney Buy
2018-04-12 Bestätigt Needham Buy
2018-02-13 Eingeleitet BTIG Research Buy
2018-01-04 Eingeleitet SunTrust Buy
2017-12-01 Fortgesetzt H.C. Wainwright Buy
2016-11-16 Bestätigt RBC Capital Mkts Outperform
2016-10-05 Bestätigt Needham Buy
2016-09-16 Eingeleitet H.C. Wainwright Buy
2015-03-30 Eingeleitet Needham Buy
2015-03-30 Eingeleitet Oppenheimer Outperform
Alle ansehen

Summit Therapeutics Inc Aktie (SMMT) Neueste Nachrichten

pulisher
Mar 23, 2025

Is Summit Therapeutics a Millionaire Maker? - Nasdaq

Mar 23, 2025
pulisher
Mar 22, 2025

Cantor Fitzgerald Initiates Coverage of Summit Therapeutics (BMV:SMMT) with Overweight Recommendation - Nasdaq

Mar 22, 2025
pulisher
Mar 22, 2025

Summit rises as Cantor becomes latest to launch with a bullish view - MSN

Mar 22, 2025
pulisher
Mar 21, 2025

Cantor Fitzgerald Initiates Coverage of Summit Therapeutics (SMMT) with Overweight Recommendation - Nasdaq

Mar 21, 2025
pulisher
Mar 21, 2025

Summit Therapeutics grants stock options to new employees By Investing.com - Investing.com Canada

Mar 21, 2025
pulisher
Mar 21, 2025

Summit Therapeutics grants stock options to new employees - Investing.com India

Mar 21, 2025
pulisher
Mar 21, 2025

Summit Therapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4) -March 21, 2025 at 04:20 pm EDT - Marketscreener.com

Mar 21, 2025
pulisher
Mar 21, 2025

Summit Therapeutics Awards 147,500 Shares in Strategic Employee Stock Options - StockTitan

Mar 21, 2025
pulisher
Mar 21, 2025

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance UK

Mar 21, 2025
pulisher
Mar 21, 2025

Summit stock rises after Cantor's bullish view (SMMT:NASDAQ) - Seeking Alpha

Mar 21, 2025
pulisher
Mar 21, 2025

Cantor Fitzgerald Initiates Summit Therapeutics at Overweight -March 21, 2025 at 07:27 am EDT - Marketscreener.com

Mar 21, 2025
pulisher
Mar 19, 2025

This Unstoppable Biotech Stock Just Became an Even Better Buy - The Globe and Mail

Mar 19, 2025
pulisher
Mar 18, 2025

Summit Therapeutics Names Robert LaCaze as Chief Commercial Officer -March 18, 2025 at 03:30 am EDT - Marketscreener.com

Mar 18, 2025
pulisher
Mar 17, 2025

Summit Therapeutics : Completion of $50 million Fundraising and Directorate Change - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Billion-Dollar Oncology Expert Robert LaCaze to Drive Summit Therapeutics Cancer Drug Launch - StockTitan

Mar 17, 2025
pulisher
Mar 17, 2025

Evercore ISI Group Initiates Coverage of Summit Therapeutics (BMV:SMMT) with Outperform Recommendation - Nasdaq

Mar 17, 2025
pulisher
Mar 16, 2025

Summit gains as Evercore highlights potential to rival Merck’s Keytruda - MSN

Mar 16, 2025
pulisher
Mar 16, 2025

Applovin, Super Micro Computer And Intel Among Top 10 Large-Cap Gainers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio? - Benzinga

Mar 16, 2025
pulisher
Mar 16, 2025

Summit Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:SMMT - Benzinga

Mar 16, 2025
pulisher
Mar 14, 2025

(SMMT) On The My Stocks Page - Stock Traders Daily

Mar 14, 2025
pulisher
Mar 14, 2025

Summit Therapeutics issues stock options to new employees By Investing.com - Investing.com Australia

Mar 14, 2025
pulisher
Mar 14, 2025

Summit Therapeutics issues stock options to new employees - Investing.com India

Mar 14, 2025
pulisher
Mar 14, 2025

Summit Therapeutics Awards 122,650 Shares in Employee Stock Options at $18.50 - StockTitan

Mar 14, 2025
pulisher
Mar 14, 2025

Summit Therapeutics Stock Climbs 4%, Share Price Hits $19.96 - TradingPedia

Mar 14, 2025
pulisher
Mar 14, 2025

Why Summit Therapeutics Stock Was Winning This Week - MSN

Mar 14, 2025
pulisher
Mar 14, 2025

SMMT Gains on Bullish Analyst Coverage - GuruFocus.com

Mar 14, 2025
pulisher
Mar 14, 2025

Summit Therapeutics (NASDAQ:SMMT) Coverage Initiated at Evercore ISI - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

Is Summit Therapeutics Inc. (SMMT) the Best Multibagger Stock to Buy in 2025? - Insider Monkey

Mar 13, 2025
pulisher
Mar 13, 2025

This Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This Year - Nasdaq

Mar 13, 2025
pulisher
Mar 12, 2025

Evercore ISI Initiates Summit Therapeutics at Outperform With $30 Price Target -March 12, 2025 at 12:08 pm EDT - Marketscreener.com

Mar 12, 2025
pulisher
Mar 12, 2025

Summit Therapeutics Shares Surge on Promising Trial Results - TipRanks

Mar 12, 2025
pulisher
Mar 12, 2025

Evercore ISI Group Initiates Coverage of Summit Therapeutics (SMMT) with Outperform Recommendation - Nasdaq

Mar 12, 2025
pulisher
Mar 12, 2025

Summit Therapeutics initiated with an Outperform at Evercore ISI - TipRanks

Mar 12, 2025
pulisher
Mar 11, 2025

12 Best Multibagger Stocks to Buy in 2025 - Insider Monkey

Mar 11, 2025
pulisher
Mar 11, 2025

Stifel maintains Buy on Summit Therapeutics, $40 target By Investing.com - Investing.com Canada

Mar 11, 2025
pulisher
Mar 08, 2025

Summit Therapeutics Inc. (SMMT): Why Are Analysts Bullish On This Hot Growth Stock Right Now? - Insider Monkey

Mar 08, 2025
pulisher
Mar 05, 2025

New York State Common Retirement Fund Grows Stake in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World

Mar 05, 2025
pulisher
Mar 05, 2025

Principal Financial Group Inc. Acquires 147,003 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World

Mar 05, 2025
pulisher
Mar 05, 2025

Summit Therapeutics (NASDAQ:SMMT) Stock Rating Upgraded by StockNews.com - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

(SMMT) Investment Analysis and Advice - Stock Traders Daily

Mar 04, 2025
pulisher
Mar 04, 2025

Rhumbline Advisers Has $2.23 Million Stock Position in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World

Mar 04, 2025
pulisher
Mar 01, 2025

Summit Therapeutics (NASDAQ:SMMT) Earns Buy Rating from Analysts at The Goldman Sachs Group - MarketBeat

Mar 01, 2025
pulisher
Mar 01, 2025

Equities Analysts Offer Predictions for SMMT Q1 Earnings - MarketBeat

Mar 01, 2025
pulisher
Mar 01, 2025

Summit Therapeutics' (SMMT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

Mar 01, 2025
pulisher
Mar 01, 2025

Goldman Sachs Initiates Coverage of Summit Therapeutics (SMMT) with Buy Recommendation - MSN

Mar 01, 2025
pulisher
Feb 28, 2025

StockNews.com Downgrades Summit Therapeutics (NASDAQ:SMMT) to Sell - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga

Feb 28, 2025
pulisher
Feb 28, 2025

Summit Therapeutics Stock Surges Amid Promising Trials - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Goldman Sachs Initiates Summit Therapeutics at Buy With $42 Price Target -February 28, 2025 at 08:12 am EST - Marketscreener.com

Feb 28, 2025

Finanzdaten der Summit Therapeutics Inc-Aktie (SMMT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$33.70
price up icon 0.60%
$79.92
price up icon 1.46%
$312.99
price down icon 0.19%
$95.38
price down icon 0.88%
biotechnology ONC
$251.98
price down icon 4.04%
Kapitalisierung:     |  Volumen (24h):